RBC Capital on Pacira Pharmaceuticals (PCRX): 'regulatory approval of the generic form is just one piece of a larger puzzle'
Tweet Send to a Friend
RBC Capital analyst Daniel Busb reiterated an Outperform rating and $45.00 price target on Pacira Pharmaceuticals (NASDAQ: PCRX)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
